Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies the side effects and how well imatinib mesylate works in
treating patients with uterine cancer that has failed to respond to initial chemotherapy or
has re-grown after therapy. Imatinib mesylate may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.